EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 13
Issue: 7
Year: 2026

MUCOADHESIVE DRUG DELIVERY SYSTEM: A COMPREHENSIVE REVIEW

B. Premkumar*, D. Dhachinamoorthi, M. Vikashini

Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, Eachanari, Coimbatore - 641 021, Tamil Nadu, India. [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai].

***Corresponding Author: B. Premkumar**

Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, Eachanari, Coimbatore – 641 021, Tamil Nadu, India. [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai].

DOI: https://doi.org/10.5281/zenodo.21292732

How to cite this Article: B. Premkumar*, D. Dhachinamoorthi, M. Vikashini. (2026). Mucoadhesive Drug Delivery System: A Comprehensive Review. European Journal of Biomedical and Pharmaceutical Sciences, 13(7), 450–455.

Article Received on 15/06/2026 **Article Revised on 05/07/2026** **Article Published on 10/07/2026**

ABSTRACT

Mucoadhesive drug delivery systems (MDDS) are advanced pharmaceutical formulations designed to adhere to the mucosal surfaces of the body, such as the buccal, nasal, ocular, vaginal, rectal, and gastrointestinal mucosa. These systems enhance the residence time of the drug at the site of absorption, thereby improving drug bioavailability, reducing dosing frequency, and increasing patient compliance. Mucoadhesion is achieved through the interaction between mucoadhesive polymers and the mucus layer, allowing controlled and sustained drug release. Various natural, semi-synthetic, and synthetic polymers, including chitosan, sodium alginate, carbopol, hydroxypropyl methylcellulose (HPMC), and polycarbophil, are commonly used in these formulations. Mucoadhesive drug delivery systems are particularly beneficial for drugs that undergo extensive first-pass metabolism, have a short biological half-life, or require localized therapy. Despite challenges such as variability in mucus turnover and limited adhesion time, continuous advancements in polymer science and nanotechnology have significantly improved the effectiveness of these systems. Overall, mucoadhesive drug delivery represents a promising approach for enhancing therapeutic efficacy, minimizing systemic side effects, and providing targeted and sustained drug delivery.

KEYWORDS: Mucoadhesion, Mucoadhesive drug delivery system, Bioadhesion, Mucoadhesive polymers, Controlled drug release, Buccal delivery, Nasal delivery, Drug bioavailability, Sustained release, Targeted drug delivery.

INTRODUCTION

Drug delivery systems have undergone remarkable advancements over the past few decades, with increasing emphasis on improving therapeutic efficacy, patient compliance, and targeted drug delivery. Conventional drug delivery methods often suffer from several limitations, including poor bioavailability, rapid drug clearance, frequent dosing, and extensive first-pass metabolism, which may reduce the therapeutic effectiveness of many drugs. To overcome these challenges, novel drug delivery systems have been developed, among which mucoadhesive drug delivery systems (MDDS) have emerged as a promising and effective approach.

Mucoadhesive drug delivery systems are pharmaceutical formulations designed to adhere to the mucus layer covering various mucosal tissues, including the buccal, nasal, ocular, gastrointestinal, vaginal, and rectal mucosa. The intimate contact established between the dosage form and the mucosal surface prolongs the residence time of the formulation at the site of application, thereby enhancing drug absorption, improving bioavailability, reducing dosing frequency, and minimizing systemic side effects. These systems are particularly advantageous for drugs with poor oral bioavailability, short biological half-life, or those that undergo extensive hepatic first-pass metabolism.

The concept of mucoadhesion is based on the interaction between mucoadhesive polymers and mucin glycoproteins present in the mucus layer. These interactions involve various mechanisms, including hydrogen bonding, electrostatic attraction, van der Waals forces, and polymer chain interpenetration. A wide range of natural, semi-synthetic, and synthetic polymers, such

as chitosan, sodium alginate, carbopol, hydroxypropyl methylcellulose (HPMC), polycarbophil, and cellulose derivatives, have been investigated for their excellent mucoadhesive properties and ability to provide controlled and sustained drug release.

Recent advances in pharmaceutical technology and nanotechnology have further expanded the applications of mucoadhesive drug delivery systems. The integration of nanoparticles, liposomes, microspheres, hydrogels, and in situ gels with mucoadhesive polymers has enabled the development of innovative formulations with enhanced drug stability, site-specific targeting, and improved therapeutic outcomes. These systems have demonstrated considerable potential in the treatment of various local and systemic diseases, including oral infections, ocular disorders, nasal conditions, gastrointestinal diseases, vaginal infections, and chronic disorders requiring prolonged drug administration.

Despite their numerous advantages, mucoadhesive drug delivery systems also face challenges such as variability in mucus composition and turnover, limited adhesion duration, enzymatic degradation, and patient-specific physiological factors that may influence drug absorption. Ongoing research focuses on the development of novel polymers, multifunctional biomaterials, and smart drug delivery platforms capable of overcoming these limitations and improving clinical performance.

This review article aims to provide a comprehensive overview of mucoadhesive drug delivery systems, including the principles and mechanisms of mucoadhesion, classification and characteristics of mucoadhesive polymers, formulation strategies, factors affecting mucoadhesion, evaluation methods, routes of administration, recent technological advances, therapeutic applications, current challenges, and future perspectives. Exploring these aspects highlights the growing significance of mucoadhesive drug delivery systems as an innovative strategy for enhancing drug delivery and optimizing patient care.

Mechanism of Mucoadhesion

Mucoadhesion is a complex physicochemical process by which a drug delivery system adheres to a mucosal surface through interactions between mucoadhesive polymers and the mucus layer. The mechanism involves a sequence of events that results in the formation of a stable adhesive bond, thereby prolonging the residence time of the dosage form and enhancing drug absorption. Although the exact mechanism varies depending on the polymer, the mucosal tissue, and environmental conditions, mucoadhesion is generally described as occurring in two sequential stages: the contact stage and the consolidation stage.

1. Contact Stage

The contact stage is the initial phase of mucoadhesion in which the mucoadhesive dosage form comes into close contact with the mucosal surface. This contact may occur due to physiological movements, external application, or hydration of the dosage form. During this stage, the formulation spreads over the mucus layer, allowing intimate interaction between the polymer and the mucin glycoproteins. Adequate wetting and swelling of the polymer are essential for maximizing the contact area and facilitating adhesion.

2. Consolidation Stage

Following initial contact, the consolidation stage involves the strengthening of adhesive interactions between the polymer chains and the mucus layer. Hydration causes the polymer to swell and become flexible, enabling polymer chains to interpenetrate with the mucin network. Various intermolecular forces, including hydrogen bonding, electrostatic interactions, van der Waals forces, hydrophobic interactions, and, in some cases, covalent bonding, contribute to the formation of a stable adhesive interface. This stage determines the strength and duration of mucoadhesion.

Molecular Mechanism of Mucoadhesion

The molecular mechanism of mucoadhesion involves several interconnected processes:

- **Wetting and hydration:** The polymer absorbs water from the mucus layer, increasing its flexibility and facilitating intimate contact with the mucosal surface.
- **Polymer swelling:** Swelling exposes additional functional groups capable of interacting with mucin molecules and enhances chain mobility.
- **Interpenetration of polymer chains:** Flexible polymer chains diffuse into the glycoprotein network of mucus, creating an interpenetrating network that strengthens adhesion.
- **Formation of secondary chemical bonds:** Hydrogen bonds, ionic interactions, van der Waals forces, and hydrophobic interactions stabilize the adhesive interface.
- **Mechanical entanglement:** Physical entanglement of polymer and mucin chains further enhances adhesive strength and prolongs retention.

Theories of Mucoadhesion

Several theories have been proposed to explain the mechanism of mucoadhesion. No single theory completely explains all aspects of the process; therefore, mucoadhesion is generally considered to result from a combination of these mechanisms.

1. Electronic Theory

This theory suggests that adhesion occurs due to electron transfer between the mucoadhesive polymer and the mucosal surface, creating an electrical double layer at the interface. The resulting attractive electrostatic forces contribute to adhesion.

2. Wetting Theory

According to this theory, a liquid or low-viscosity

adhesive spreads over the mucosal surface, producing intimate contact. The degree of wetting depends on the surface tension and contact angle of the adhesive system. Better spreading results in stronger adhesion.

3. Diffusion Theory
The diffusion theory proposes that polymer chains diffuse into the mucin glycoprotein network and become physically entangled. The extent of diffusion depends on polymer chain flexibility, molecular weight, cross-linking density, and contact time.

4. Adsorption Theory
This theory states that adhesion occurs through the formation of primary and secondary chemical bonds after initial contact. Secondary interactions, including hydrogen bonding, van der Waals forces, hydrophobic interactions, and electrostatic attraction, are primarily responsible for mucoadhesion because they are reversible and biocompatible.

5. Mechanical Theory
According to the mechanical theory, adhesive materials penetrate into the irregularities and pores present on the mucosal surface, resulting in mechanical interlocking that enhances adhesive strength.

6. Fracture Theory
The fracture theory evaluates the force required to separate the adhesive from the mucosal surface. It is particularly useful for measuring the mechanical strength of mucoadhesive bonds and comparing different formulations.

Factors Influencing the Mechanism of Mucoadhesion
The effectiveness of mucoadhesion is influenced by several formulation- and physiological-related factors, including:

- Polymer molecular weight and chain flexibility
- Polymer concentration and degree of cross-linking
- Hydration and swelling behavior
- Functional groups capable of hydrogen bonding
- Surface charge of the polymer
- pH and ionic strength of the surrounding environment
- Thickness and turnover rate of the mucus layer
- Contact time between the formulation and mucosal tissue
- Physiological conditions such as saliva secretion, mucus renewal, and enzymatic activity

Advantages of Mucoadhesive Microspheres
Mucoadhesive microspheres are multiparticulate drug delivery systems designed to adhere to mucosal surfaces and provide controlled and targeted drug release. By combining the benefits of microsphere technology with mucoadhesive polymers, these systems improve therapeutic efficacy, enhance drug bioavailability, and increase patient compliance. The major advantages of mucoadhesive microspheres are as follows:

1. Prolonged Residence Time
Mucoadhesive microspheres adhere to the mucus layer of various mucosal tissues, including the buccal, nasal, ocular, gastrointestinal, vaginal, and rectal mucosa. This prolonged residence time allows the drug to remain at the absorption site for an extended period, improving therapeutic effectiveness.

2. Enhanced Bioavailability
The increased contact time between the drug and the mucosal surface promotes greater drug absorption. Mucoadhesive microspheres are particularly beneficial for drugs with poor oral bioavailability or those that undergo extensive first-pass hepatic metabolism.

3. Controlled and Sustained Drug Release
These microspheres can be formulated to release drugs in a controlled and sustained manner over prolonged periods. This helps maintain therapeutic drug concentrations, reduces plasma concentration fluctuations, and minimizes the need for frequent dosing.

4. Improved Patient Compliance
Reduced dosing frequency and the non-invasive nature of mucoadhesive microspheres improve patient adherence to therapy, especially in the management of chronic diseases requiring long-term medication.

5. Site-Specific Drug Delivery
Mucoadhesive microspheres enable localized drug delivery by retaining the drug at the target mucosal site. This targeted approach increases drug concentration at the desired site while reducing systemic exposure and associated adverse effects.

6. Avoidance of First-Pass Metabolism
When administered through buccal, nasal, rectal, or vaginal routes, mucoadhesive microspheres can bypass hepatic first-pass metabolism, resulting in improved systemic drug availability and therapeutic efficacy.

7. Reduced Drug Degradation
The mucoadhesive polymer matrix can protect drugs from enzymatic degradation and harsh physiological conditions, particularly within the gastrointestinal tract, thereby enhancing drug stability.

8. Uniform Drug Distribution
As multiparticulate systems, microspheres distribute more uniformly over the mucosal surface than single-unit dosage forms, reducing localized irritation and improving absorption.

9. Reduced Dose and Side Effects
Improved drug absorption and sustained release allow effective therapy with lower doses, thereby reducing the risk of dose-related toxicity and systemic side effects.

10. Flexibility in Formulation
Mucoadhesive microspheres can be prepared using a wide variety of natural, semi-synthetic, and synthetic polymers. Their physicochemical properties can be tailored to achieve desired drug release profiles, adhesion strength, and stability.

11. Versatility of Administration
Mucoadhesive microspheres are suitable for multiple routes of administration, including:

- Buccal
- Nasal
- Ocular
- Gastrointestinal
- Vaginal
- Rectal
- Pulmonary (in selected formulations)

This versatility expands their application across numerous therapeutic areas.

12. Improved Stability During Storage
Appropriately formulated mucoadhesive microspheres exhibit good physical and chemical stability, protecting encapsulated drugs from moisture, oxidation, and environmental degradation, thereby extending shelf life.

13. Potential for Macromolecule Delivery
Mucoadhesive microspheres show promise in the delivery of peptides, proteins, vaccines, and nucleic acids by increasing residence time at mucosal surfaces and enhancing absorption while protecting these sensitive molecules from degradation.

14. Better Therapeutic Outcomes
By combining prolonged residence time, sustained drug release, improved bioavailability, and targeted drug delivery, mucoadhesive microspheres provide enhanced therapeutic efficacy and improve overall treatment outcomes.

Applications of Mucoadhesive Microspheres
Mucoadhesive microspheres have gained significant attention in pharmaceutical research because of their ability to prolong drug residence time at mucosal surfaces, enhance bioavailability, and provide controlled and targeted drug delivery. Their versatility allows their application across various routes of administration and therapeutic areas. The major applications of mucoadhesive microspheres are discussed below.

1. Buccal Drug Delivery
Mucoadhesive microspheres are widely used for buccal drug delivery due to their ability to adhere to the buccal mucosa and provide prolonged drug release. This route avoids hepatic first-pass metabolism, enhances systemic bioavailability, and improves patient compliance. Drugs such as analgesics, antihypertensive agents, antiemetics, and peptides have been successfully formulated as buccal mucoadhesive microspheres.

2. Nasal Drug Delivery
The nasal cavity provides a highly vascularized mucosal surface suitable for both local and systemic drug delivery. Mucoadhesive microspheres prolong nasal residence time by reducing mucociliary clearance, thereby increasing drug absorption. They are used for the delivery of peptides, proteins, vaccines, hormones, and drugs intended for rapid systemic action or direct nose-to-brain transport.

3. Ocular Drug Delivery
Conventional ophthalmic formulations are rapidly removed from the eye by blinking and tear drainage, resulting in poor drug bioavailability. Mucoadhesive microspheres adhere to the conjunctival and corneal mucosa, increasing ocular residence time and improving drug absorption. They are used in the treatment of glaucoma, conjunctivitis, dry eye syndrome, and other ocular diseases.

4. Gastrointestinal Drug Delivery
In the gastrointestinal tract, mucoadhesive microspheres remain attached to the gastric or intestinal mucosa for extended periods, allowing prolonged drug release and improved absorption. This approach is particularly beneficial for drugs with a narrow absorption window or those requiring local treatment of gastrointestinal disorders such as gastric ulcers, inflammatory bowel disease, and *Helicobacter pylori* infection.

5. Vaginal Drug Delivery
Mucoadhesive microspheres enhance the retention of drugs within the vaginal cavity, reducing leakage and improving therapeutic efficacy. They are extensively used for the treatment of fungal, bacterial, and viral infections, contraception, hormone replacement therapy, and localized drug delivery.

6. Rectal Drug Delivery
Rectal mucoadhesive microspheres improve drug retention and absorption while partially avoiding hepatic first-pass metabolism. They are useful for administering drugs to pediatric, geriatric, and unconscious patients or when oral administration is unsuitable.

7. Pulmonary Drug Delivery
Mucoadhesive microspheres have potential applications in pulmonary drug delivery by increasing the residence time of inhaled drugs within the respiratory tract. They may improve the treatment of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary infections while reducing dosing frequency.

8. Delivery of Peptides and Proteins
Peptides and proteins are susceptible to enzymatic degradation and exhibit poor oral bioavailability. Mucoadhesive microspheres protect these biomolecules from degradation, prolong mucosal contact, and enhance their absorption across mucosal membranes, making

them promising carriers for insulin, calcitonin, growth hormone, and other therapeutic proteins.

9. Vaccine Delivery
Mucoadhesive microspheres are increasingly investigated as carriers for mucosal vaccines. By adhering to mucosal surfaces, they prolong antigen exposure to immune cells and enhance both mucosal and systemic immune responses. This strategy has shown promise for oral, nasal, and vaginal immunization.

10. Targeted Drug Delivery
The incorporation of mucoadhesive polymers into microspheres enables localized and site-specific drug delivery. This targeted approach increases drug concentration at the desired site while minimizing systemic exposure and reducing adverse effects. Such systems are valuable in treating localized infections, inflammatory disorders, and cancers affecting mucosal tissues.

11. Controlled and Sustained Drug Delivery
Mucoadhesive microspheres provide controlled and prolonged drug release, maintaining therapeutic drug concentrations for extended periods. This reduces dosing frequency, minimizes fluctuations in plasma drug levels, and enhances patient adherence to long-term therapy.

12. Colon-Specific Drug Delivery
Mucoadhesive microspheres can be designed to deliver drugs specifically to the colon by combining pH-sensitive polymers with mucoadhesive materials. These systems are useful for the treatment of ulcerative colitis, Crohn's disease, colorectal cancer, and other colonic disorders.

13. Gene and Nucleic Acid Delivery
Recent advances in nanotechnology and polymer science have expanded the application of mucoadhesive microspheres for delivering DNA, RNA, plasmids, and small interfering RNA (siRNA). These systems protect nucleic acids from degradation and enhance their transport across mucosal barriers, supporting developments in gene therapy.

14. Cancer Therapy
Mucoadhesive microspheres have been investigated for the localized delivery of anticancer drugs to oral, gastrointestinal, cervical, and colorectal tumors. Prolonged residence time at the tumor site enhances local drug concentration while reducing systemic toxicity and improving therapeutic outcomes.

CONCLUSION

Mucoadhesive drug delivery systems have emerged as one of the most promising advances in modern pharmaceutical technology, offering an effective strategy to overcome the limitations associated with conventional dosage forms. The incorporation of mucoadhesive polymers into microsphere-based formulations has significantly improved drug residence time at mucosal surfaces, resulting in enhanced drug absorption, increased bioavailability, controlled and sustained drug release, and improved therapeutic efficacy. These systems are capable of adhering to various mucosal tissues, including the buccal, nasal, ocular, gastrointestinal, vaginal, and rectal mucosa, making them highly versatile for both local and systemic drug delivery.

Mucoadhesive microspheres provide several advantages over conventional formulations, including reduced dosing frequency, minimized fluctuations in plasma drug concentrations, protection of drugs from enzymatic degradation, and partial or complete avoidance of hepatic first-pass metabolism. Furthermore, they facilitate site-specific drug targeting, thereby reducing systemic drug exposure and minimizing adverse effects. Their multiparticulate nature also promotes uniform distribution over the mucosal surface, improving the consistency of drug absorption while lowering the risk of local irritation.

Recent advances in polymer science, nanotechnology, and biodegradable biomaterials have expanded the scope of mucoadhesive microspheres beyond conventional drug delivery. These systems are increasingly being explored for the delivery of peptides, proteins, vaccines, nucleic acids, and other biologically active molecules that require protection from degradation and enhanced mucosal permeability. The development of stimuli-responsive polymers, ligand-mediated targeting approaches, and multifunctional carrier systems has further improved the precision and efficiency of mucoadhesive drug delivery.

Despite these significant advantages, certain challenges remain, including variability in mucus turnover, differences in mucosal physiology among patients, limited residence time under dynamic physiological conditions, and the need for polymers with improved biocompatibility and stronger adhesive properties. Addressing these limitations through continued research into novel mucoadhesive materials, advanced formulation techniques, and optimized manufacturing processes will be essential for translating these systems into broader clinical applications.

Overall, mucoadhesive microspheres represent a highly effective and innovative drug delivery platform capable of enhancing therapeutic outcomes through prolonged mucosal residence, targeted drug delivery, and controlled drug release. Their ability to improve the efficacy and safety of a wide range of pharmaceutical agents makes them an attractive option for the treatment of both local and systemic diseases. With ongoing advances in pharmaceutical sciences, biomaterials, and nanomedicine, mucoadhesive microspheres are expected to play an increasingly important role in the development of next-generation drug delivery systems and

personalized medicine, contributing to safer, more effective, and patient-friendly therapeutic strategies in the future.

REFERENCES

1. Senthil A, Narayanaswamy VB, Ajit I, Galge DS, Bhosale RS. Mucoadhesive microspheres. *International Journal of Ayurvedic and Pharmaceutical Research*, 2011; 2(1): 55–59.
2. Kataria S, Middha A, Sandhu P, Bilandi A, Kapoor B. Microspheres: A review. *International Journal of Research in Pharmacy and Chemistry*, 2011; 1(4): 1185–1198.
3. Kunisawa J, Okudaira A, Tsutsumi Y, Takahashi I, Nakanishi T, Kiyono H, et al. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. *Vaccine*, 2000; 19(4–5): 589–594.
4. Belgamwar V, Shah V, Surana SJ. Formulation and evaluation of oral mucoadhesive multiparticulate system containing metoprolol tartrate: An in vitro and ex vivo characterization. *Current Drug Delivery*, 2009; 6(1): 113–121.
5. Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide: In vitro and in vivo evaluation of bilayer tablet formulations. *Drug Development and Industrial Pharmacy*, 2000; 26(8): 857–866.
6. Yuehuei H, Friedman RJ, editors. *Handbook of Bacterial Adhesion: Principles, Methods and Applications*. Totowa, NJ: Humana Press, 2000.
7. Smart JD. The basics and underlying mechanisms of mucoadhesion. Advanced Drug Delivery Reviews, 2005; 57(11): 1556–1568.
8. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2009; 71(3): 505–518.
9. Carvalho FC, Bruschi ML, Evangelista RC, Gremião MPD. Mucoadhesive drug delivery systems. Brazilian Journal of Pharmaceutical Sciences, 2010; 46(1): 1–17.
10. Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromolecular Bioscience, 2011; 11(6): 748–764.
11. Lehr CM. From sticky stuff to sweet receptors: Achievements, limits and novel approaches to bioadhesion. European Journal of Drug Metabolism and Pharmacokinetics, 1996; 21(2): 139–148.
12. Peppas NA, Buri PA. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. Journal of Controlled Release, 1985; 2(4): 257–275.
13. Park K, Robinson JR. Bioadhesive polymers as platforms for oral-controlled drug delivery: Method to study bioadhesion. International Journal of Pharmaceutics, 1984; 19(2–3): 107–127.
14. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Advanced Drug Delivery Reviews, 1998; 34(2–3): 191–219.
15. Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug Development and Industrial Pharmacy, 1997; 23(5): 489–515.
16. Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Advanced Drug Delivery Reviews, 2005; 57(11): 1666–1691.
17. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. Journal of Pharmacy and Bioallied Sciences, 2011; 3(1): 89–100.
18. Chowdary KPR, Srinivas L. Mucoadhesive drug delivery systems: A review of current status. Indian Drugs, 2000; 37(9): 400–406.
19. Vermani K, Garg S. The scope and potential of vaginal drug delivery. Pharmaceutical Science & Technology Today, 2000; 3(10): 359–364.
20. Rathbone MJ, Drummond BK, Tucker IG. Oral Mucosal Drug Delivery. New York: Marcel Dekker 1994.
21. Nagai T, editor. Mucoadhesive Drug Delivery Systems. Tokyo: CRC Press, 1993.
22. Smart JD. Drug delivery using buccal-adhesive systems. Advanced Drug Delivery Reviews, 1993; 11(3): 253–270.